Tevogen Bio Holdings Inc. (TVGN )

Currency in USD Disclaimer
$1.37 +$0.28 (25.69%)
Closed 10/15/2024
$0.86
$1.45
$0.26
$21.09

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol TVGN
  • Company Tevogen Bio Holdings Inc.
  • Price $1.37
  • Changes Percentage 25.69
  • Change 0.28
  • Day Low $0.86
  • Day High $1.45
  • Year High $21.09
  • Year Low $0.26
  • Market Cap $94,136,480
  • Price Avg 50 EMA (D) $0.49
  • Price Avg 200 EMA (D) $3.01
  • Exchange NASDAQ
  • Volume 56,196,611
  • Average Volume 4,848,315
  • Open $1
  • Previous Close $1.09
  • EPS 0.06
  • PE 22.83
  • Earnings Announcement 2024-05-27 04:00:00
  • Shares Outstanding $68,712,759

Company brief: TEVOGEN BIO HOLDINGS INC. (TVGN )

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

TVGN Corporation News

Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions

Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions

October 15, 2024 at 2:30 pm ET

globenewswire.com -- WARREN, N.J., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf...

Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company's Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use

Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company's Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use

October 15, 2024 at 11:36 am ET

globenewswire.com -- WARREN, N.J., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf...

Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024

Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024

October 11, 2024 at 3:59 pm ET

globenewswire.com -- WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf...

Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

October 11, 2024 at 12:12 pm ET

globenewswire.com -- WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf...

Income Statement